Abstract
Compromised vascular endothelial barrier function is a salient feature of diabetic complications such as sight-threatening diabetic macular edema (DME). Current standards of care for DME manage aspects of the disease, but require frequent intravitreal administration and are poorly effective in large subsets of patients. Here we provide evidence that an elevated burden of senescent cells in the retina triggers cardinal features of DME pathology and conduct an initial test of senolytic therapy in patients with DME. In cell culture models, sustained hyperglycemia provoked cellular senescence in subsets of vascular endothelial cells displaying perturbed transendothelial junctions associated with poor barrier function and leading to micro-inflammation. Pharmacological elimination of senescent cells in a mouse model of DME reduces diabetes-induced retinal vascular leakage and preserves retinal function. We then conducted a phase 1 single ascending dose safety study of UBX1325 (foselutoclax), a senolytic small-molecule inhibitor of BCL-xL, in patients with advanced DME for whom anti-vascular endothelial growth factor therapy was no longer considered beneficial. The primary objective of assessment of safety and tolerability of UBX1325 was achieved. Collectively, our data suggest that therapeutic targeting of senescent cells in the diabetic retina with a BCL-xL inhibitor may provide a long-lasting, disease-modifying intervention for DME. This hypothesis will need to be verified in larger clinical trials. ClinicalTrials.gov identifier: NCT04537884.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Data availability
Requests for additional information, reagents or material resources should be addressed to P.S. Sequencing data from STZ-treated mouse retinas have been deposited in NCBI’s Gene Expression Omnibus under accession number GSE211583. Datasets used to perform single-cell transcriptomic analyses on mouse diabetic retinas were previously published and are publicly available under the accession number GSE178121. Datasets used to perform bulk transcriptomic analyses on rat diabetic retinas were previously published and are publicly available under the accession number GSE20886. All information on materials and reagents is provided in Supplementary Information. All clinical data have been provided in the paper in the form of figures, in the text or in Supplementary Information (including the clinical trial protocol, STROBE checklist and the statistical analysis plan). Additional requests for clinical data should be addressed to the corresponding author and may be provided upon reasonable request. Source data are provided with this paper.
References
Antonetti, D. A., Klein, R. & Gardner, T. W. Diabetic retinopathy. N. Engl. J. Med. 366, 1227–1239 (2012).
Levine, S. R., Sapieha, P., Dutta, S., Sun, J. K. & Gardner, T. W. It is time for a moonshot to find “Cures” for diabetic retinal disease. Prog. Retin. Eye Res. 90, 101051 (2022).
Stitt, A. W. et al. The progress in understanding and treatment of diabetic retinopathy. Prog. Retin. Eye Res. 51, 156–186 (2016).
Yu, D. Y. et al. Retinal capillary perfusion: spatial and temporal heterogeneity. Prog. Retin. Eye Res. 70, 23–54 (2019).
Duh, E. J., Sun, J. K. & Stitt, A. W. Diabetic retinopathy: current understanding, mechanisms, and treatment strategies. JCI Insight 2, e93751 (2017).
Heier, J. S. et al. Intravitreal aflibercept for diabetic macular edema: 148-week results from the VISTA and VIVID studies. Ophthalmology 123, 2376–2385 (2016).
Scott, A. W., Bressler, N. M., Ffolkes, S., Wittenborn, J. S. & Jorkasky, J. Public attitudes about eye and vision health. JAMA Ophthalmol. 134, 1111–1118 (2016).
Bressler, N. M. et al. Persistent macular thickening following intravitreous aflibercept, bevacizumab, or ranibizumab for central-involved diabetic macular edema with vision impairment: a secondary analysis of a randomized clinical trial. JAMA Ophthalmol. 136, 257–269 (2018).
Rofagha, S. et al. Seven-year outcomes in ranibizumab-treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN-UP). Ophthalmology 120, 2292–2299 (2013).
Comparison of Age-related Macular Degeneration Treatments Trials Research Group. et al. Five-year outcomes with anti-vascular endothelial growth factor treatment of neovascular age-related macular degeneration: the comparison of age-related macular degeneration treatments trials. Ophthalmology 123, 1751–1761 (2016).
Robinson, G. S. et al. Nonvascular role for VEGF: VEGFR-1, 2 activity is critical for neural retinal development. FASEB J. 15, 1215–1217 (2001).
Kurihara, T., Westenskow, P. D., Bravo, S., Aguilar, E. & Friedlander, M. Targeted deletion of Vegfa in adult mice induces vision loss. J. Clin. Invest. 122, 4213–4217 (2012).
Berber, P., Grassmann, F., Kiel, C. & Weber, B. H. An eye on age-related macular degeneration: the role of microRNAs in disease pathology. Mol. Diagn. Ther. 21, 31–43 (2017).
Saint-Geniez, M. et al. Endogenous VEGF is required for visual function: evidence for a survival role on Müller cells and photoreceptors. PLoS ONE 3, e3554 (2008).
Jones, R. 3rd & Rhee, D. J. Corticosteroid-induced ocular hypertension and glaucoma: a brief review and update of the literature. Curr. Opin. Ophthalmol. 17, 163–167 (2006).
Little, H. L. Treatment of proliferative diabetic retinopathy. Long-term results of argon laser photocoagulation. Ophthalmology 92, 279–283 (1985).
Coppe, J. P. et al. Senescence-associated secretory phenotypes reveal cell-nonautonomous functions of oncogenic RAS and the p53 tumor suppressor. PLoS Biol. 6, 2853–2868 (2008).
Coppé, J. -P., Desprez, P. -Y., Krtolica, A. & Campisi, J. The senescence-associated secretory phenotype: the dark side of tumor suppression. Annu. Rev. Pathol. 5, 99–118 (2010).
Yamazaki, Y. et al. Vascular cell senescence contributes to blood–brain barrier breakdown. Stroke 47, 1068–1077 (2016).
Oubaha, M. et al. Senescence-associated secretory phenotype contributes to pathological angiogenesis in retinopathy. Sci. Transl. Med. 8, 362ra144 (2016).
Binet, F. et al. Neutrophil extracellular traps target senescent vasculature for tissue remodeling in retinopathy. Science 369, eaay5356 (2020).
Crespo-Garcia, S. et al. Pathological angiogenesis in retinopathy engages cellular senescence and is amenable to therapeutic elimination via BCL-xL inhibition. Cell Metab. 33, 818–832 (2021).
Palmer, A. K. et al. Cellular senescence in type 2 diabetes: a therapeutic opportunity. Diabetes 64, 2289–2298 (2015).
Thompson, P. J. et al. Targeted elimination of senescent beta cells prevents type 1 diabetes. Cell Metab. 29, 1045–1060 (2019).
Aguayo-Mazzucato, C. et al. Acceleration of beta cell aging determines diabetes and senolysis improves disease outcomes. Cell Metab. 30, 129–142 (2019).
Su, L. et al. Diabetic endothelial cells differentiated from patient iPSCs show dysregulated glycine homeostasis and senescence associated phenotypes. Front. Cell Dev. Biol. 9, 667252 (2021).
Lamoke, F. et al. Increased oxidative and nitrative stress accelerates aging of the retinal vasculature in the diabetic retina. PLoS ONE 10, e0139664 (2015).
Singh, R., Letai, A. & Sarosiek, K. Regulation of apoptosis in health and disease: the balancing act of BCL-2 family proteins. Nat. Rev. Mol. Cell Biol. 20, 175–193 (2019).
Bao, L. et al. The S100A6 calcium-binding protein regulates endothelial cell-cycle progression and senescence. FEBS J. 279, 4576–4588 (2012).
VanGuilder, H. D. et al. Multi-modal proteomic analysis of retinal protein expression alterations in a rat model of diabetic retinopathy. PLoS ONE 6, e16271 (2011).
Sun, L. et al. Single cell RNA sequencing (scRNA-seq) deciphering pathological alterations in streptozotocin-induced diabetic retinas. Exp. Eye Res. 210, 108718 (2021).
Miloudi, K. et al. NOTCH1 signaling induces pathological vascular permeability in diabetic retinopathy. Proc. Natl Acad. Sci. USA 116, 4538–4547 (2019).
Yoon, C. H. et al. Diabetes-induced Jagged1 overexpression in endothelial cells causes retinal capillary regression in a murine model of diabetes mellitus: insights into diabetic retinopathy. Circulation 134, 233–247 (2016).
Okamoto, A., Iwamoto, Y. & Maru, Y. Oxidative stress-responsive transcription factor ATF3 potentially mediates diabetic angiopathy. Mol. Cell. Biol. 26, 1087–1097 (2006).
Karthikkeyan, G. et al. Hyperglycemia induced early growth response-1 regulates vascular dysfunction in human retinal endothelial cells. Microvasc. Res. 117, 37–43 (2018).
Venu, V. K. P. et al. Metformin prevents hyperglycemia-associated, oxidative stress-induced vascular endothelial dysfunction: essential role for the orphan nuclear receptor human nuclear receptor 4A1 (Nur77). Mol. Pharmacol. 100, 428–455 (2021).
Li, H. et al. Diabetes promotes retinal vascular endothelial cell injury by inducing CCN1 expression. Front. Cardiovasc. Med. 8, 689318 (2021).
You, J. J., Yang, C. M., Chen, M. S. & Yang, C. H. Regulation of Cyr61/CCN1 expression by hypoxia through cooperation of c-Jun/AP-1 and HIF-1alpha in retinal vascular endothelial cells. Exp. Eye Res. 91, 825–836 (2010).
Ao, H., Liu, B., Li, H. & Lu, L. Egr1 mediates retinal vascular dysfunction in diabetes mellitus via promoting p53 transcription. J. Cell. Mol. Med. 23, 3345–3356 (2019).
Bruemmer, D. et al. Regulation of the growth arrest and DNA damage-inducible gene 45 (GADD45) by peroxisome proliferator-activated receptor gamma in vascular smooth muscle cells. Circ. Res. 93, e38–e47 (2003).
Hoare, M. et al. NOTCH1 mediates a switch between two distinct secretomes during senescence. Nat. Cell Biol. 18, 979–992 (2016).
Passegue, E. & Wagner, E. F. JunB suppresses cell proliferation by transcriptional activation of p16INK4a expression. EMBO J. 19, 2969–2979 (2000).
Bertelli, P. M. et al. Long term high glucose exposure induces premature senescence in retinal endothelial cells. Front. Physiol. 13, 929118 (2022).
Murakami, T., Felinski, E. A. & Antonetti, D. A. Occludin phosphorylation and ubiquitination regulate tight junction trafficking and vascular endothelial growth factor-induced permeability. J. Biol. Chem. 284, 21036–21046 (2009).
Murakami, T., Frey, T., Lin, C. & Antonetti, D. A. Protein kinase cbeta phosphorylates occludin regulating tight junction trafficking in vascular endothelial growth factor-induced permeability in vivo. Diabetes 61, 1573–1583 (2012).
Huber, A. H. et al. The cadherin cytoplasmic domain is unstructured in the absence of beta-catenin. A possible mechanism for regulating cadherin turnover. J. Biol. Chem. 276, 12301–12309 (2001).
Claesson-Welsh, L., Dejana, E. & McDonald, D. M. Permeability of the endothelial barrier: identifying and reconciling controversies. Trends Mol. Med. 27, 314–331 (2021).
Zhu, Y. et al. Identification of a novel senolytic agent, navitoclax, targeting the Bcl-2 family of anti-apoptotic factors. Aging Cell 15, 428–435 (2016).
Zhu, Y. et al. The Achilles’ heel of senescent cells: from transcriptome to senolytic drugs. Aging Cell 14, 644–658 (2015).
Gonzalez-Gualda, E., Baker, A. G., Fruk, L. & Munoz-Espin, D. A guide to assessing cellular senescence in vitro and in vivo. FEBS J. 288, 56–80 (2021).
Chang, J. et al. Clearance of senescent cells by ABT263 rejuvenates aged hematopoietic stem cells in mice. Nat. Med. 22, 78–83 (2016).
Yosef, R. et al. Directed elimination of senescent cells by inhibition of BCL-W and BCL-XL. Nat. Commun. 7, 11190 (2016).
Smith, L. E. et al. Oxygen-induced retinopathy in the mouse. Invest. Ophthalmol. Vis. Sci. 35, 101–111 (1994).
Baker, D. J. et al. Clearance of p16Ink4a-positive senescent cells delays ageing-associated disorders. Nature 479, 232–236 (2011).
Gonzalez, V. H. et al. Early and long-term responses to anti-vascular endothelial growth factor therapy in diabetic macular edema: analysis of protocol I data. Am. J. Ophthalmol. 172, 72–79 (2016).
Wykoff, C. C. et al. Pharmacokinetics of the port delivery system with ranibizumab in the Ladder phase 2 trial for neovascular age-related macular degeneration. Ophthalmol. Ther. 11, 1705–1717 (2022).
Faricimab (Vabysmo) for age-related macular degeneration and diabetic macular edema. Med. Lett. Drugs Ther. 64, 45-46 (2022).
Abouhish, H. et al. Inhibition of HDAC6 attenuates diabetes-induced retinal redox imbalance and microangiopathy. Antioxidants 9, 599 (2020).
Gericke, A., Suminska-Jasinska, K. & Breborowicz, A. Sulodexide reduces glucose induced senescence in human retinal endothelial cells. Sci. Rep. 11, 11532 (2021).
Mortuza, R., Feng, B. & Chakrabarti, S. miR-195 regulates SIRT1-mediated changes in diabetic retinopathy. Diabetologia 57, 1037–1046 (2014).
Thounaojam, M. C. et al. MicroRNA-34a (miR-34a) mediates retinal endothelial cell premature senescence through mitochondrial dysfunction and loss of antioxidant activities. Antioxidants 8, 328 (2019).
Diabetes, C. et al. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N. Engl. J. Med. 329, 977–986 (1993).
Nentwich, M. M. & Ulbig, M. W. Diabetische retinopathie. Der Diabetol. 6, 491–502 (2010).
Antonetti, D. A., Silva, P. S. & Stitt, A. W. Current understanding of the molecular and cellular pathology of diabetic retinopathy. Nat. Rev. Endocrinol. 17, 195–206 (2021).
Mattapallil, M. J. et al. The Rd8 mutation of the Crb1 gene is present in vendor lines of C57BL/6N mice and embryonic stem cells, and confounds ocular induced mutant phenotypes. Invest. Ophthalmol. Vis. Sci. 53, 2921–2927 (2012).
Melsted, P. et al. Modular, efficient and constant-memory single-cell RNA-seq preprocessing. Nat. Biotechnol. 39, 813–818 (2021).
Hao, Y. et al. Integrated analysis of multimodal single-cell data. Cell 184, 3573–3587 (2021).
Skinnider, M. A. et al. Cell type prioritization in single-cell data. Nat. Biotechnol. 39, 30–34 (2021).
Hanzelmann, S., Castelo, R. & Guinney, J. GSVA: gene set variation analysis for microarray and RNA-seq data. BMC Bioinformatics 14, 7 (2013).
Liberzon, A. et al. The Molecular Signatures Database (MSigDB) hallmark gene set collection. Cell Syst. 1, 417–425 (2015).
Acknowledgements
P.S. holds the Wolfe Professorship in Translational Research, a Canada Research Chair in Retinal Cell Biology as well as the Fonds de Recherche en Ophtalmologie de l’Université de Montréal Endowed Chair. S.C.-G. holds a fellowship from the Fonds de Recherche du Québec - Santé (FRQ-S) and the Montreal Diabetes Research Center. This work was supported by UNITY Biotechnology. Other funding was provided from operating grants to P.S. from Diabetes Canada (DI-3-18-5444-PS), the Canadian Institutes of Health Research (Foundation grant 353770), The Alcon Research Institute Senior Investigator Award and The Heart and Stroke Foundation of Canada (G-16-00014658) and BrightFocus Foundation (M2022015I). Additional support was provided by the Fonds de Recherche en Ophtalmologie de l’Université de Montréal (FROUM), the Réseau en Recherche en Santé de la Vision (RRSV) and the FRQ-S/RRSV-funded Single-Cell Academy. We thank V. Guber for the management of the mouse colony, the research assistants at the animal facilities, and M. Sergeev at the microscope core facilities of the Hospital Maisonneuve-Rosemont Research Center for all their technical support throughout the duration of this project. We also thank H. Findlay and G. Mawambo for the technical assistance provided, and B. Larrivée for reagents.
Author information
Authors and Affiliations
Contributions
P.S., S.C.-G., J. Dananberg, A.G. and L.S. designed the study with contribution from P.R.T.; S.C.-G., F.F., R.D.-M., G.C., G.B., I.H., R.R., R.J. and P.P. performed research; F.A.R. provided human specimens; S.C.-G., F.F., R.D.-M., G.C., G.B., R.R., M.B., A.D., S.C., P.P., P.R.T., P.J.B. and P.S. analyzed data; S.C.-G. prepared the figures; P.S. and S.C.-G. wrote the paper with contributions from P.R.T., A.G., F.A.M., S.K., D.R., J. Dananberg, P.J.B., A.M.W. and M.H. All authors revised and approved the submitted version of the paper.
Corresponding author
Ethics declarations
Competing interests
P.S., J. Dananberg, A.G., L.S. and A.N. are executives at UNITY Biotechnology. N.D. is the founder of UNITY Biotechnology. S.K., D.R., L.M., P.P., P.J.B., A.N., J.D., L.S. and P.R.T. were employees of UNITY Biotechnology during the time this project was developed and hold shares in the company. S.C.-G., R.D.-M., F.F., G.C., A.D., A.M.W. and J.-S.J. have contract work with UNITY Biotechnology. The other authors declare no competing interests.
Peer review
Peer review information
Nature Medicine thanks William Keyes and the other, anonymous, reviewer(s) for their contribution to the peer review of this work. Primary Handling Editor: Michael Basson, in collaboration with the Nature Medicine team.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Extended data
Supplementary information
Supplementary Information
Supplementary Fig. 1. mRNA expression of OCLN and CDH5 in glucose-treated HRMECs. Relative to Fig. 2. Supplementary Fig. 2. UBX1967 selectively induces apoptosis in radiation-induced senescent human retina microvascular ECs. Supplementary Fig. 3. UBX1967 selectively induces apoptosis in high-glucose-induced senescent human retina microvascular ECs. Supplementary Fig. 4. Effect of a single dose of UBX1325 in patients with nAMD. Relative to Fig. 4. Supplementary Table 1. Human vitreous patient data Supplementary Table 2. Human histology patient data Supplementary Table 3. UBX0601 pharmacokinetics in vitro. Supplementary Table 4. Ocular TEAEs by severity of all patients administered UBX1325 (DME + nAMD patients). Supplementary Table 5. Summary of BCVA in DME patients (course of 24 weeks). Supplementary Table 6. Primary antibodies list. Supplementary Table 7. RT–qPCR primer list. Supplementary Note 1. Clinical trial protocol. Supplementary Note 2. Clinical trial STROBE checklist. Supplementary Note 3. Clinical trial statistical analysis plan.
Source data
Source Data Fig. 1
Unprocessed western blots (combined file).
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Crespo-Garcia, S., Fournier, F., Diaz-Marin, R. et al. Therapeutic targeting of cellular senescence in diabetic macular edema: preclinical and phase 1 trial results. Nat Med 30, 443–454 (2024). https://doi.org/10.1038/s41591-024-02802-4
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41591-024-02802-4